Biomedical Engineering Reference
In-Depth Information
chronic obstructive pulmonary disease who continue smoking. European
Respiratory Society Study on Chronic Obstructive Pulmonary Disease.
N Engl J Med 1999; 340:1948-1953.
42. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term
effect of inhaled budesonide in mild and moderate chronic obstructive
pulmonary disease: a randomized controlled trial. Lancet 1999; 353:
1819-1823.
43. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK.
Randomised, double blind, placebo controlled study of fluticasone propionate
in patients with moderate to severe chronic obstructive pulmonary disease: the
ISOLDE trial. BMJ 2000; 320:1297-1303.
44. Effect of inhaled triamcinolone on the decline in pulmonary function in
chronic obstructive pulmonary disease. Lung Health Study Research Group
2000; 343:1902-1909.
45. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in
chronic obstructive pulmonary disease: a systematic review of randomized
placebo-controlled trials. Am J Med 2002; 113:59-65.
46. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and
oral glucocorticoids on inflammatory indices in asthma and COPD. Am J
Respir Crit Care Med 1997; 155:542-548.
47. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ.
Effect of high dose inhaled steroid on cells, cytokines, and proteases in
induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit
Care Med 1999; 160:1635-1639.
48. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects
of inhaled fluticasone on airway inflammation in chronic obstructive pulmon-
ary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit
Care Med 2002; 165:1592-1596.
49. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell RE, Donnelly LE, et al.
Impaired inhibition by dexamethasone of cytokine release by alveolar macro-
phages from patients with chronic obstructive pulmonary disease. Am J
Respir Crit Care Med 2003; 167:24-31.
50. Russell RE, Culpitt SV, DeMatos C, Donnelly L, Smith M, Wiggins J, et al.
Release and activity of matrix metalloproteinase-9 and tissue inhibitor of
metalloproteinase-1 by alveolar macrophages from patients with chronic
obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002; 26:602-609.
51. Payne DN, Adcock IM. Molecular mechanisms of corticosteroid actions.
Paediatr Respir Rev 2001; 2:145-150.
52. Malchoff DM, Brufsky A, Reardon G, McDermott P, Javier EC, Bergh CH,
et al. A mutation of the glucocorticoid receptor in primary cortisol resistance.
J Clin Invest 1993; 91:1918-1925.
53. Clark KD, Wardrobe-Wong N, Snashall PD. Endogenous cortisol and lung
damage in a predominantly smoking population. Am J Respir Crit Care
Med 1999; 159:755-759.
54. Scalvini S, Volterrani M, Vitacca M, Clark AL, Solfrini R, Panzali AM, et al.
Plasma hormone levels and haemodynamics in patients with chronic obstruc-
tive lung disease. Monaldi Arch Chest Dis 1996; 51:380-386.
